AR069965A1 - Derivado de (gamma)-lactona de esteroide de acido 15, 16 -metilen-17-hidroxi-19-nor-21-carboxilico, su uso para preparar un medicamento que lo contiene y medicamento que contiene al compuesto - Google Patents
Derivado de (gamma)-lactona de esteroide de acido 15, 16 -metilen-17-hidroxi-19-nor-21-carboxilico, su uso para preparar un medicamento que lo contiene y medicamento que contiene al compuestoInfo
- Publication number
- AR069965A1 AR069965A1 ARP080105702A ARP080105702A AR069965A1 AR 069965 A1 AR069965 A1 AR 069965A1 AR P080105702 A ARP080105702 A AR P080105702A AR P080105702 A ARP080105702 A AR P080105702A AR 069965 A1 AR069965 A1 AR 069965A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- alkyl
- group
- product containing
- medicinal product
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
Abstract
Derivado de gamma-lactona de esteroide de ácido 15,16-metilen-17-hidroxi-19-nor-21-carboxílico que tiene la formula química general (1), Z se selecciona del grupo que comprende oxígeno, dos átomos de hidrogeno, NOR' y NNHSO2R', donde R' es hidrogeno, alquilo C1-10, arilo o aralquilo C7-20, R4 se selecciona del grupo que comprende hidrogeno y halogeno, donde además R6a, R6b se seleccionan de manera independiente del grupo que comprende hidrogeno, alquilo C1-10, alquenilo C2-10 y alquinilo C2-10, o forman juntos metileno o 1,2-etandiilo, y R7 se selecciona del grupo que comprende hidrogeno, alquilo C1-10, cicloalquilo C3-6, alquenilo C2-10 y alquinilo C2-10, o R6a, R7 son juntos un átomo de oxígeno o metileno, o se suprimen al formarse un enlace doble entre C6 y C7, y R6b se selecciona del grupo que comprende hidrogeno, alquilo C1-10, alquenilo C2-10 y alquinilo C2-10, y R18 es hidrogeno o alquilo C1-3 y también sus solvatos, hidratos, estereoisomeros, y sales. Estos compuestos son utiles para la contracepcion y para el tratamiento de trastornos pre, peri y posmenopáusicos y de molestias premenstruales. Los derivados presentan un efecto gestagénico y en casos preferidos, adicionalmente un efecto antimineralcorticoide y neutro a ligeramente androgénico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007063501A DE102007063501A1 (de) | 2007-12-29 | 2007-12-29 | 15, 16-Methylen-17-hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069965A1 true AR069965A1 (es) | 2010-03-03 |
Family
ID=40627627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105702A AR069965A1 (es) | 2007-12-29 | 2008-12-23 | Derivado de (gamma)-lactona de esteroide de acido 15, 16 -metilen-17-hidroxi-19-nor-21-carboxilico, su uso para preparar un medicamento que lo contiene y medicamento que contiene al compuesto |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20110015162A1 (es) |
| EP (1) | EP2238150B1 (es) |
| JP (1) | JP5643107B2 (es) |
| KR (1) | KR20100094999A (es) |
| CN (1) | CN101910191B (es) |
| AR (1) | AR069965A1 (es) |
| AU (1) | AU2008342913A1 (es) |
| BR (1) | BRPI0821432A2 (es) |
| CA (1) | CA2708394C (es) |
| CL (1) | CL2008003920A1 (es) |
| CO (1) | CO6300840A2 (es) |
| DE (1) | DE102007063501A1 (es) |
| DO (1) | DOP2010000200A (es) |
| EA (1) | EA201001006A1 (es) |
| EC (1) | ECSP10010319A (es) |
| ES (1) | ES2397972T3 (es) |
| HK (1) | HK1151801A1 (es) |
| IL (1) | IL205981A0 (es) |
| NZ (1) | NZ586452A (es) |
| PA (1) | PA8809901A1 (es) |
| PE (1) | PE20091186A1 (es) |
| TW (1) | TW200938206A (es) |
| UY (1) | UY31583A1 (es) |
| WO (1) | WO2009083269A1 (es) |
| ZA (1) | ZA201005394B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
| KR200497382Y1 (ko) | 2023-05-22 | 2023-10-25 | 주식회사밀알 | 마감판 체결이 용이한 침대 프레임 구조 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2918463A (en) | 1958-06-12 | 1959-12-22 | Searle & Co | 17-carboxyalkylated 17-hydroxy-19-norandrosten-3-ones |
| DE1183500B (de) | 1962-10-12 | 1964-12-17 | Schering Ag | Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe |
| US3705179A (en) | 1971-03-15 | 1972-12-05 | American Home Prod | Antiandrogenic steroids |
| NL7701384A (nl) | 1977-02-10 | 1978-08-14 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks. |
| DE2922500A1 (de) | 1979-05-31 | 1980-12-04 | Schering Ag | 6 beta .7 beta |
| DE3402329A1 (de) | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3410880A1 (de) * | 1984-03-21 | 1985-10-03 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 17-substituierte estradiene und estratriene |
| DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| DE102004063864A1 (de) | 2004-12-30 | 2006-07-13 | Schering Ag | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
-
2007
- 2007-12-29 DE DE102007063501A patent/DE102007063501A1/de not_active Ceased
-
2008
- 2008-12-23 BR BRPI0821432-8A patent/BRPI0821432A2/pt not_active IP Right Cessation
- 2008-12-23 EA EA201001006A patent/EA201001006A1/ru unknown
- 2008-12-23 EP EP08868567A patent/EP2238150B1/de not_active Not-in-force
- 2008-12-23 KR KR1020107014313A patent/KR20100094999A/ko not_active Application Discontinuation
- 2008-12-23 JP JP2010540080A patent/JP5643107B2/ja not_active Expired - Fee Related
- 2008-12-23 TW TW097150289A patent/TW200938206A/zh unknown
- 2008-12-23 US US12/811,002 patent/US20110015162A1/en not_active Abandoned
- 2008-12-23 AU AU2008342913A patent/AU2008342913A1/en not_active Abandoned
- 2008-12-23 CN CN2008801234324A patent/CN101910191B/zh not_active Expired - Fee Related
- 2008-12-23 PA PA20088809901A patent/PA8809901A1/es unknown
- 2008-12-23 WO PCT/EP2008/011162 patent/WO2009083269A1/de active Application Filing
- 2008-12-23 AR ARP080105702A patent/AR069965A1/es unknown
- 2008-12-23 CA CA2708394A patent/CA2708394C/en not_active Expired - Fee Related
- 2008-12-23 ES ES08868567T patent/ES2397972T3/es active Active
- 2008-12-23 NZ NZ586452A patent/NZ586452A/en not_active IP Right Cessation
- 2008-12-26 UY UY31583A patent/UY31583A1/es not_active Application Discontinuation
- 2008-12-29 CL CL2008003920A patent/CL2008003920A1/es unknown
- 2008-12-29 PE PE2008002192A patent/PE20091186A1/es not_active Application Discontinuation
-
2010
- 2010-05-26 IL IL205981A patent/IL205981A0/en unknown
- 2010-06-29 DO DO2010000200A patent/DOP2010000200A/es unknown
- 2010-06-29 EC EC2010010319A patent/ECSP10010319A/es unknown
- 2010-06-29 CO CO10078683A patent/CO6300840A2/es not_active Application Discontinuation
- 2010-07-28 ZA ZA2010/05394A patent/ZA201005394B/en unknown
-
2011
- 2011-06-08 HK HK11105765.9A patent/HK1151801A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PA8809901A1 (es) | 2009-12-16 |
| EP2238150A1 (de) | 2010-10-13 |
| PE20091186A1 (es) | 2009-09-06 |
| UY31583A1 (es) | 2009-08-03 |
| JP5643107B2 (ja) | 2014-12-17 |
| US20110015162A1 (en) | 2011-01-20 |
| CL2008003920A1 (es) | 2010-01-22 |
| DE102007063501A1 (de) | 2009-07-02 |
| WO2009083269A1 (de) | 2009-07-09 |
| TW200938206A (en) | 2009-09-16 |
| AU2008342913A1 (en) | 2009-07-09 |
| CA2708394C (en) | 2015-06-16 |
| BRPI0821432A2 (pt) | 2015-06-16 |
| DOP2010000200A (es) | 2010-07-31 |
| CN101910191B (zh) | 2013-07-31 |
| IL205981A0 (en) | 2010-11-30 |
| EA201001006A1 (ru) | 2011-02-28 |
| ES2397972T3 (es) | 2013-03-12 |
| ECSP10010319A (es) | 2010-08-31 |
| JP2011507926A (ja) | 2011-03-10 |
| EP2238150B1 (de) | 2012-10-24 |
| KR20100094999A (ko) | 2010-08-27 |
| NZ586452A (en) | 2012-04-27 |
| ZA201005394B (en) | 2014-01-29 |
| CO6300840A2 (es) | 2011-07-21 |
| HK1151801A1 (en) | 2012-02-10 |
| CN101910191A (zh) | 2010-12-08 |
| CA2708394A1 (en) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011469A (es) | Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos. | |
| AR066970A1 (es) | Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contiene | |
| CY1112201T1 (el) | Φαρμακο για τη θεραπευτικη αγωγη γριπης | |
| CY1121984T1 (el) | Μη-ορμονικοι στεροειδεις ρυθμιστες toy nf-kb για θεραπεια ασθενειας | |
| NO20073357L (no) | 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien | |
| BRPI0606895A2 (pt) | novos compostos com efeito terapêutico | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| RS51462B (en) | TRIAZOLOPYRIDINE CARBOXAMID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION | |
| MA41337A (fr) | Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3 | |
| BR112017019805A2 (pt) | composto, medicamento, composição farmacêutica, analgésico, antidepressivo, fármaco ansiolítico, métodos para melhorar, prevenir ou tratar dor, depressão, ansiedade, mal de parkinson, polaquiúria ou incontinência urinária e glaucoma, uso de um composto, agentes terapêuticos para mal de parkinson, para polaquiúria ou incontinência urinária e para glaucoma. | |
| AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos | |
| AR069965A1 (es) | Derivado de (gamma)-lactona de esteroide de acido 15, 16 -metilen-17-hidroxi-19-nor-21-carboxilico, su uso para preparar un medicamento que lo contiene y medicamento que contiene al compuesto | |
| PE20090822A1 (es) | DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE | |
| AR069963A1 (es) | Derivado 15, 16-metilen-17- (1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene | |
| AR069966A1 (es) | Derivado de (gamma)-lactona de esteroide del acido 17-hidroxi-19-nor-21-carboxilico, su uso y el medicamento que lo contiene | |
| AR069962A1 (es) | Derivados de 19-nor-esteroide que tiene un grupo 15(alfa) 16(alfa)-metileno y un anillo de 17,17-espirolactona saturado, su uso y medicamentos que los comprenden | |
| AR069964A1 (es) | Derivado de 17-(1'-propenil) -17-3' -oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen | |
| ATE452636T1 (de) | 3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen | |
| DE60144246D1 (de) | Imidazolderivate, verfahren zu deren herstellung und deren verwendung | |
| CU20100139A7 (es) | Derivados de y-lactona de esteroide de ácido 15,16-metilen-17-hidroxi-19-nor-21-carboxílico, su uso y medicamentos que contienen tal derivado | |
| TR202002069A2 (tr) | Bcl-2 i̇nhi̇bi̇törü olarak kullanilan yeni̇ küçük terapöti̇k bi̇leşi̇kleri̇n fi̇zi̇k odakli olarak keşfi̇ | |
| CU20100138A7 (es) | Derivados de 17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |